Prevention & care
Antifungal medicines: skin, scalp, nail and oral treatment are different contexts
On this page
Antifungal medicines treat infections caused by fungi. The same general category includes skin creams, liquids, shampoos and medicines taken by mouth. NHS terbinafine guidance distinguishes pharmacy skin preparations from prescribed tablets. The body site, organism and formulation matter; a familiar skin product does not establish an appropriate treatment for a nail, scalp or internal infection.[1]
Keep route and infection site attached to the medicine
| Category | Purpose or mechanism | Boundary |
|---|---|---|
| Skin clotrimazole | Imidazole antifungal cream or liquid | This preparation does not work on scalp or nails[2] |
| Skin terbinafine | Local cream, gel, spray or solution | Not interchangeable with prescribed tablets[1] |
| Oral terbinafine | Prescribed nail or other specified treatment | Systemic precautions and nail-growth timeframe matter[3] |
| Oral fluconazole | Triazole for specified yeast and other infections | Condition, interactions and pregnancy context differ[4] |
| Ketoconazole cream or shampoo | Local skin/scalp uses | Oral ketoconazole has a separate safety history[5] |
A route difference is more than a convenience choice
NHS terbinafine information describes local skin products and prescribed tablets, with different expected treatment timeframes. It emphasizes completing the intended course even when symptoms improve. A medicine that is appropriate for a superficial site may not reach the relevant target in another preparation. Conversely, an oral formulation introduces a different exposure and clinical assessment. Read the preparation and indication together rather than assuming a shared drug name permits switching between a cream and tablets.[1]
Clotrimazole skin instructions have an explicit site boundary
MedlinePlus identifies topical clotrimazole for specified skin tinea infections and states that this skin preparation does not work on the scalp or nails. It is for external skin use, and symptoms that worsen or fail to improve in the expected treatment window require assessment. That boundary is more useful than treating all scaling, itching or altered nails as a request for the same cream. Other formulations with the ingredient name retain their own instructions and purposes.[2]
Evidence & uncertainty
A 2017 Cochrane review included forty-eight oral-treatment trials with 10,200 participants whose toenail infection was confirmed by testing. Studies lasted four months to two years. Terbinafine and azoles improved clinical and laboratory cure against placebo, but recurrence and quality-of-life evidence were limited. This does not rank every antifungal for every fungal condition.[7]
Selected-source overview · Independent review pendingPublished questions
Can clotrimazole skin cream instructions be transferred to scalp or nail treatment?
Selected-source overview · Independent review pending. Read the evidence context.
No. MedlinePlus explicitly says this skin preparation does not work on scalp or nails. Body site and formulation must remain attached to its indication.[2]
Evidence behind this answer
- Clotrimazole topical drug information
official medicine guidance · 2018
Selected relevant original source page passages inspected · Imidazole skin category, site exclusions and assessment for failed/worsening response
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are topical terbinafine and prescribed terbinafine tablets interchangeable preparations?
Selected-source overview · Independent review pending. Read the evidence context.
No. NHS distinguishes local skin preparations from prescribed tablets. Their exposure, indications and treatment timeframes require their own instructions.[1]
Evidence behind this answer
- About terbinafine
official medicine guidance · 2023
Selected relevant original source page passages inspected · Local versus oral forms, indications and course/growth context
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can nail appearance take months to change after oral antifungal treatment?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. Terbinafine information explains that a healthy nail needs time to grow. Visible appearance does not independently determine treatment duration or microbiological cure.[3]
Evidence behind this answer
- Terbinafine oral drug information
official medicine guidance · 2018
Selected relevant original source page passages inspected · Nail-growth timeframe, liver/medicine precautions and urgent serious symptoms
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does every fluconazole indication use the same treatment course?
Selected-source overview · Independent review pending. Read the evidence context.
No. Its information describes several conditions and condition-dependent courses, with important medicine, pregnancy and organ-function precautions. A past prescription does not define a new regimen.[4]
Evidence behind this answer
- Fluconazole drug information
official medicine guidance · 2018
Selected relevant original source page passages inspected · Triazole, condition-dependent uses/courses and interactions/pregnancy/organ precautions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does ketoconazole shampoo guidance describe ketoconazole tablets?
Selected-source overview · Independent review pending. Read the evidence context.
No. NHS describes local skin/scalp products separately from oral tablets. The ingredient name does not make their indications or safety context identical.[5]
Evidence behind this answer
- About ketoconazole cream and shampoo
official medicine guidance · 2024
Selected relevant original source page passages inspected · Local skin/scalp purposes, irritation and distinct oral-tablet context
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the MHRA liver-injury warning concern oral rather than all topical ketoconazole?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. The dated communication distinguishes oral fungal treatment from creams and shampoos with very low systemic absorption. Keep route attached to the warning.[6]
Evidence behind this answer
- Oral ketoconazole liver-injury warning
official medicine guidance · 2013
Selected relevant original source page passages inspected · August 2013 article, online 2014: oral fungal-use risk/benefit and explicit topical exception
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The appearance of a nail changes on a growth timeframe
Oral terbinafine information explains that healthy nail growth can take months after treatment, so appearance and microbiological response are not identical outcomes. It asks about liver disease, other medicines and pregnancy, and lists potentially serious symptoms including jaundice, dark urine or severe rash that need immediate medical contact. A slow visible change is not permission to extend or intensify treatment independently. The prescribed preparation has systemic precautions that cannot be inferred from a skin cream.[3]
The same oral antifungal can have different clinical purposes
Fluconazole information describes treatment of yeast and other fungal infections in several body sites and prevention in particular high-risk settings. It distinguishes condition-dependent treatment courses and advises discussion of other medicines, heart rhythm, kidney or liver disease and pregnancy. Those are separate clinical situations, not one universal single-course remedy. A previously used prescription does not establish a new diagnosis or the same treatment duration, even if the symptom seems familiar or the medicine name is unchanged.[4]
A shampoo and a tablet can share a name without sharing an indication
NHS describes ketoconazole cream and shampoo for specified skin and scalp conditions, including dandruff and seborrheic dermatitis. Its page separately notes that oral tablets generally concern a rare endocrine condition and are outside that skin-product explanation. This distinction keeps topical fungal treatment from becoming a claim about every oral preparation. Local irritation is a possible adverse effect, and prevention of a recurring scalp problem may follow different instructions from treatment of a new skin infection.[5]
A route-specific warning should retain its route and date
MHRA’s August 2013 article, published online in 2014, warned against oral ketoconazole for fungal infections because liver-injury risks outweighed benefits. It distinguished creams and shampoos, which had very low systemic absorption and could continue in approved use. The current NHS skin-product explanation is consistent with keeping these routes separate. This history illustrates why a serious warning about a swallowed medicine should not automatically be attached to every topical product containing the same ingredient.[6]
Cure definitions and trial populations limit a broad ranking
The oral-toenail review found terbinafine probably more effective than azoles for appearance and laboratory cure, while recurrence comparisons were less certain. Most participants were adults in dermatology settings with confirmed, mainly dermatophyte infection; many studies had design limitations. No study assessed quality of life. These results should retain that population and outcome rather than being generalized to every rash, yeast infection or immunocompromised patient. Nail appearance, laboratory clearance and relief of daily difficulties are distinct questions.[7]
References
- About terbinafine
Official medicine guidance
NHS · Content/publication date: 2023
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: Local versus oral forms, indications and course/growth context - Clotrimazole topical drug information
Official medicine guidance
MedlinePlus / ASHP · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: Imidazole skin category, site exclusions and assessment for failed/worsening response - Terbinafine oral drug information
Official medicine guidance
MedlinePlus / ASHP · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: Nail-growth timeframe, liver/medicine precautions and urgent serious symptoms - Fluconazole drug information
Official medicine guidance
MedlinePlus / ASHP · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: Triazole, condition-dependent uses/courses and interactions/pregnancy/organ precautions - About ketoconazole cream and shampoo
Official medicine guidance
NHS · Content/publication date: 2024
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: Local skin/scalp purposes, irritation and distinct oral-tablet context - Oral ketoconazole liver-injury warning
Official medicine guidance
MHRA · Content/publication date: 2013
Accessed: 2026-10-13 UTC · Selected relevant original source page passages inspected
Cited sections: August 2013 article, online 2014: oral fungal-use risk/benefit and explicit topical exception - Oral antifungal medication for toenail infection
Systematic review
Kreijkamp-Kaspers and colleagues / Cochrane · Content/publication date: 2017
Accessed: 2026-10-13 UTC · Original summary and abstract methods/results inspected; full review and included trials not independently appraised
Cited sections: Summary/abstract: confirmed infection,48 trials,10200 participants,4 months–2 years, cure versus recurrence/quality-of-life limits
Scope & review
- Population
- Readers of fungal skin/scalp/nail medicines; oral-toenail trials mainly tested confirmed adult dermatophyte infections
- Exposure or intervention
- Topical skin/shampoo and oral antifungal preparations, including ingredient-specific site and systemic limits
- Comparison
- Skin versus scalp/nail/internal infection; topical versus oral routes; clinical appearance versus mycological cure; tested oral toenail treatments versus broad category claims
- Outcomes
- Clinical appearance, mycological cure, recurrence, local irritation and systemic safety; quality-of-life trial gaps
- Timeframe
- Preparation-specific courses and months of nail growth;2017 review trials lasted 4 months–2 years and search reached October 2016
- Jurisdiction
- UK NHS/MHRA and US MedlinePlus; historical oral-ketoconazole warning retains route and date
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added a bounded selected-source medicine explanation in edition 4.5; expert review remains unfinished.
What this article still leaves open
- How do organism, site and resistance affect comparative treatment outcomes?
- Which treatments improve recurrence and quality of life rather than laboratory cure alone?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.